The drug, which is meant to treat Type 2 diabetes, was compared with Novo Nordisk’s oral semaglutide, and showed greater improvements in blood sugar levels, known as A1C, and greater weight loss.

Eli Lilly (LLY) stock is in focus as the company posts detailed data from a late-stage trial for its obesity pill ...

Eli Lilly (LLY) and Company announced positive topline results from ACHIEVE-3, an open-label randomized Phase 3 clinical trial evaluating the safety and efficacy of orforglipron compared to oral ...